Related references
Note: Only part of the references are listed.A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis
Shoji Ichikawa et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations
Shoji Ichikawa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Hyperostosis-hyperphosphatemia syndrome:: A congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23
Yaacov Frishberg et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Itaru Urakawa et al.
NATURE (2006)
A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification
I Chefetz et al.
HUMAN GENETICS (2005)
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis
K Araya et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis
T Larsson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis:: Evidence that the disorder is autosomal recessive
S Ichikawa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
A Benet-Pagès et al.
HUMAN MOLECULAR GENETICS (2005)
Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders
Y Frishberg et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2005)
Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed
T Larsson et al.
ENDOCRINOLOGY (2005)
Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis
O Topaz et al.
NATURE GENETICS (2004)
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
KB Jonsson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia
Y Yamazaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Share Paper
